Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

(MedPage Today) — First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Among a total of 557 patients, and…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117347

Author :

Publish date : 2025-09-08 00:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

Malnutrition and Infection Rates Increase Before IBD Surgery

Related Posts

Large Jump in Poison Center Calls Tied to Self-Harm in Preteens

Another Man Gets a Pig Kidney as Transplant Trials Are Poised to Start

Alzheimer’s Disease Exacerbated by Air Pollution, Autopsy Study Suggests

BMI Proves Reliable for Youth Adiposity Detection

NIH Chief Becomes Loomer’s Next Target

Later Breakfast Tied to Morbidity, Mortality in Older Adults

Large Jump in Poison Center Calls Tied to Self-Harm in Preteens

Another Man Gets a Pig Kidney as Transplant Trials Are Poised to Start

Alzheimer’s Disease Exacerbated by Air Pollution, Autopsy Study Suggests

BMI Proves Reliable for Youth Adiposity Detection

NIH Chief Becomes Loomer’s Next Target

Later Breakfast Tied to Morbidity, Mortality in Older Adults

Self-Monitoring, Ad Infinitum

Postoperative Crizotinib Fails in Early Lung Cancer

Categories

Archives